Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) EBT Margin (2016 - 2025)

Historic EBT Margin for Niagen Bioscience (NAGE) over the last 17 years, with Q3 2025 value amounting to 14.12%.

  • Niagen Bioscience's EBT Margin rose 67800.0% to 14.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.04%, marking a year-over-year increase of 154200.0%. This contributed to the annual value of 8.89% for FY2024, which is 148000.0% up from last year.
  • Per Niagen Bioscience's latest filing, its EBT Margin stood at 14.12% for Q3 2025, which was up 67800.0% from 12.01% recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's EBT Margin registered a high of 25.7% during Q4 2024, and its lowest value of 51.17% during Q3 2021.
  • For the 5-year period, Niagen Bioscience's EBT Margin averaged around 11.61%, with its median value being 6.88% (2022).
  • As far as peak fluctuations go, Niagen Bioscience's EBT Margin tumbled by -214400bps in 2021, and later surged by 361200bps in 2023.
  • Quarter analysis of 5 years shows Niagen Bioscience's EBT Margin stood at 29.98% in 2021, then skyrocketed by 77bps to 6.88% in 2022, then surged by 108bps to 0.54% in 2023, then skyrocketed by 4678bps to 25.7% in 2024, then tumbled by -45bps to 14.12% in 2025.
  • Its EBT Margin stands at 14.12% for Q3 2025, versus 12.01% for Q2 2025 and 17.16% for Q1 2025.